NCT05240612View on ClinicalTrials.gov

A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 2, 2022

Primary Completion Date

September 14, 2023

Study Completion Date

December 28, 2023

Conditions
HTLV-1-Associated Myelopathy (HAM)
Interventions
BIOLOGICAL

MT-3921

Solution for infusion; Intravenous (IV)

BIOLOGICAL

Placebo

Solution for infusion; Intravenous (IV)

Trial Locations (1)

216-8511

St. Marianna University Hospital, Kawasaki-shi

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY